Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | CTOR stock touches 52-week low at $0.9 amid market challenges | 2 | Investing.com | ||
Fr | CTOR-Aktie erreicht 52-Wochen-Tief bei 0,9 US-Dollar | 1 | Investing.com Deutsch | ||
11.11. | Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients ... | 97 | PR Newswire | Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled27%... ► Artikel lesen | |
09.10. | CTOR-Aktie erreicht 52-Wochen-Tief bei 1,02 US-Dollar | 3 | Investing.com Deutsch | ||
01.10. | CTOR stock touches 52-week low at $1.29 amid market challenges | 1 | Investing.com | ||
13.09. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 1 | SEC Filings | ||
05.09. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 1 | SEC Filings | ||
28.08. | CTOR stock touches 52-week low at $1.67 amid market challenges | 1 | Investing.com | ||
CITIUS ONCOLOGY Aktie jetzt für 0€ handeln | |||||
16.08. | Citius Oncology Inc. completes strategic acquisition | 2 | Investing.com | ||
16.08. | CITIUS ONCOLOGY, INC. - 8-K, Current Report | 2 | SEC Filings | ||
13.08. | CTOR stock touches 52-week low at $3.20 amid market fluctuations | 1 | Investing.com | ||
13.08. | NSE - CITIUS ONCOLOGY, INC. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 1 | SEC Filings | ||
12.08. | Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. | 150 | PR Newswire | LYMPHIR for the treatment of cutaneous T-cell lymphoma approved by the FDA
Citius Pharmaceuticals, Inc. holds approximately 90% of publicly traded Citius Oncology, Inc.
Shares of Citius Oncology, Inc.... ► Artikel lesen | |
09.08. | CITIUS ONCOLOGY, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
09.08. | TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination with Citius Oncology, and Provides Market Update | 679 | GlobeNewswire (Europe) | New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- On August 7, 2024, TenX Keane Acquisition (Nasdaq: TENKU, TENK, TENKR) ("TenX"), a publicly traded special purpose acquisition company, was notified by... ► Artikel lesen | |
05.08. | Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. | 256 | PR Newswire | Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc.
Citius Pharmaceuticals to retain approximately 90% majority control post transaction... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MEDIGENE | 1,550 | 0,00 % | PTA-News: Medigene AG: Medigene präsentiert Daten zu innovativer IFN-Gamma-Biosensor-Technologie bei SITC 2024 | DJ PTA-News: Medigene AG: Medigene präsentiert Daten zu innovativer IFN-Gamma-Biosensor-Technologie bei SITC 2024
Unternehmensmitteilung für den Kapitalmarkt
Planegg/Martinsried (pta/12.11.2024/13:00)... ► Artikel lesen | |
BB BIOTECH | 39,300 | +1,68 % | PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen | DJ PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
QIAGEN | 41,045 | +2,05 % | Qiagen NV-Aktie büßt 0,31 Prozent ein (39,06 €) | Im Minus liegt zur Stunde der Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 39,06 Euro. An der Börse liegt die Qiagen NV-Aktie aktuell im Minus. Das Papier verbilligte sich um 12 Cent. Das Wertpapier... ► Artikel lesen | |
NOVAVAX | 8,130 | +0,02 % | NOVAVAX INC - 8-K, Current Report | ||
STRYKER | 369,80 | +0,05 % | Stryker Stock May Gain From Oculan Lighting Platform's Launch | ||
ILLUMINA | 135,20 | +0,48 % | Illumina-Aktie kaum gefragt: Kurs bricht um 3,47 Prozent ein (123,0856 €) | Die Aktie von Illumina zählt heute zu den großen Verlierern an der Börse. Das Papier verliert deutlich an Wert. Kein guter Tag bislang für Inhaber von Illumina: Die Aktie weist derzeit einen Kursrückgang... ► Artikel lesen | |
CRISPR THERAPEUTICS | 46,000 | 0,00 % | Why Is CRISPR Therapeutics AG (CRSP) Among the Worst Performing Biotech Stocks in 2024? | ||
AAP IMPLANTATE | 2,080 | +1,96 % | EQS-Adhoc: aap Implantate AG: Anhebung der EBITDA Guidance | EQS-Ad-hoc: aap Implantate AG / Schlagwort(e): Prognoseänderung
aap Implantate AG: Anhebung der EBITDA Guidance
18.11.2024 / 20:12 CET/CEST
Veröffentlichung einer Insiderinformation nach... ► Artikel lesen | |
OCUGEN | 0,873 | +0,58 % | Ocugen Receives Orphan Medicinal Product Designation From EMA For OCU410ST | ||
SANGAMO THERAPEUTICS | 1,882 | +4,55 % | Sangamo stock climbs 12% post-market on FDA update for ST-503 | ||
INTELLIA THERAPEUTICS | 13,715 | -0,11 % | Gen-Schere Hoffnungsträger Intellia Therapeutics: Aktie mit Kurssprung - die Hintergründe | Das Gros der Biotech- und Pharmawerte hat in den vergangenen Tagen nach der Ankündigung Donald Trumps, Robert F. Kennedy Jr. als Gesundheitsminister für die künftige Regierung nominieren zu wollen,... ► Artikel lesen | |
SCORPIUS | 0,665 | 0,00 % | Scorpius Holdings Introduces Scorpius Ventures | ||
EDITAS MEDICINE | 2,405 | +2,87 % | Editas Medicine, Inc.: Editas Medicine Announces Third Quarter 2024 Results and Business Updates | Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,361 | -1,63 % | Defence Therapeutics Inc.: Defence Announces Closing of Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 7,286 | -0,36 % | BioCryst Pharmaceuticals, Inc.: BioCryst Launches ORLADEYO (berotralstat) in Ireland |